Human disease
hemorrhagic disease
Mondo defines it as: “Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (blood coagulation disorders) or another abnormality causing a structural flaw in the blood vessels (hemostatic disorders).”
2 disease groups in OMIA reach this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 113 | Bleeding disorder | The group's name | 4 | Human disease |
37.5
|
| 112 | Bleeding diathesis | The group's name | 1 | Human disease |
31.5
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Aminocaproic Acid | None of these genes | Approved |
| Aprotinin | None of these genes | Approved |
| Coagulation Factor Ix Recombinant Human | None of these genes | Approved |
| Dicumarol | None of these genes | Approved |
| Ethanolamine Oleate | None of these genes | Approved |
| Pentastarch | None of these genes | Approved |
| Phytonadione | None of these genes | Approved |
| Protamine Sulfate | None of these genes | Approved |
| Thrombin | None of these genes | Approved |
| Andexanet Alfa | None of these genes | Awaiting approval |
| Vatreptacog Alfa (Activated) | None of these genes | Phase 3 |
| Eltrombopag | None of these genes | Phase 2 |
| Nafamostat | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.